Use of artemether-lumefantrine to treat malaria during pregnancy: What do we know and need to know?

Expert Review of Anti-Infective Therapy

Volumn 11, Issue 2, 2013, Pages 125-135

  Mutabingwa, Theonest K ^a   Adam, Ishag ^b  

^a HUBERT KAIRUKI MEMORIAL UNIVERSITY   (Tanzania)

^b UNIVERSITY OF KHARTOUM   (Sudan)

Author keywords

artemether lumefantrine; artemether lumefantrine and pregnancy; artemisinin resistance; deranged pharmacokinetics; pharmacovigillance; postmarketing surveillance; safety

Indexed keywords

ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE; ARTESUNATE PLUS MEFLOQUINE; BENFLUMETOL; CHLORPROGUANIL PLUS DAPSONE; CLINDAMYCIN; DIHYDROARTEMISININ; DIHYDROARTEMISININ PLUS PIPERAQUINE; MEFLOQUINE; NEVIRAPINE; PYRIMETHAMINE PLUS SULFADOXINE; QUININE;

ABORTION; ANEMIA; ANTIMALARIAL DRUG RESISTANCE; AREA UNDER THE CURVE; ATAXIA; CHEMISTRY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; FAT INTAKE; FIRST TRIMESTER PREGNANCY; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID DIET; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; MATERNAL TREATMENT; NEUROLOGIC DISEASE; NONHUMAN; NYSTAGMUS; OTOTOXICITY; PATIENT COMPLIANCE; PHARMACODYNAMICS; PLASMODIUM FALCIPARUM; POSTMARKETING SURVEILLANCE; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN MANIFESTATION; SLURRED SPEECH; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TINNITUS; TREMOR;

ANTIMALARIALS; ARTEMISININS; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; FLUORENES; HIV INFECTIONS; HUMANS; MALARIA; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC; PREGNANCY TRIMESTERS;

EID: 84873905585     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.12.169     Document Type: Review

References (54)

1. WHO. Technical Expert Group meeting on intermittent preventive treatment in pregnancy (IPTp). WHO Headquarters, Geneva, Switzerland (2007).
2. Desai M, ter Kuile FO, Nosten F et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect. Dis. 7(2), 93-104 (2007).
3. Dellicour S, Tatem AJ, Guerra CA, Snow RW, ter Kuile FO. Quantifying the number of pregnancies at risk of malaria in 2007: a demographic study. PLoS Med. 7(1), e1000221 (2010).
4. WHO. Guideline for the Treatment of Malaria. Second edition. WHO Headquarters, Geneva, Switzerland (2010).
5. Barnes KI, Durrheim DN, Little F et al. Effect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa. PLoS Med. 2(11), e330 (2005).
6. Sutherland CJ, Ord R, Dunyo S et al. Reduction of malaria transmission to Anopheles mosquitoes with a six-dose regimen of co-artemether. PLoS Med. 2(4), e92 (2005).
7. Duffy PE, Mutabingwa TK. Drug combinations for malaria: time to ACT? Lancet 363(9402), 3-4 (2004).
8. Chizema-Kawesha E, Mukonka VM, Mwanza M et al. Evidence of substantial nationwide reduction of malaria cases and deaths due to scale up of malaria control activities in Zambia, 2001-2008. In: Impact Evaluation Mission Report. WHO, Geneva, Switzerland (2009).
9. WHO. Deployment of artemether-lumefantrine with rapid diagnostic tests at Community level, Raya Valley, Tigray, Ethiopia. In: WHO Global Malaria Programme, Geneva, Switzerland. 1-6 (2009).
10. Lefevre G, Marrast AC, Grueninger H. Novartis Malaria Initiative: best practice example of pharmaceutical industry's engagement in the fight against malaria. Ann. N. Y. Acad. Sci. 1222, 19-29 (2011).
11. Lawford H, Zurovac D, O'Reilly L et al. Adherence to prescribed artemisinin-based combination therapy in Garissa and Bunyala districts, Kenya. Malar. J. 10, 281 (2011).
12. Mace KE, Mwandama D, Jafali J et al. Adherence to treatment with artemether- lumefantrine for uncomplicated malaria in rural Malawi. Clin. Infect. D. 53(8), 772-779 (2011).
13. Cohen JL, Yavuz E, Morris A, Arkedis J, Sabot O. Do patients adhere to over-thecounter artemisinin combination therapy for malaria? Evidence from an intervention study in Uganda. Malar. J. 11, 83 (2012).
14. Dondorp AM, Nosten F, Yi P et al. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361(5), 455-467 (2009). Coartem, package insert. Novartis, Basel, Switzerland.
15. Premji ZG, Abdulla S, Ogutu B et al. The content of African diets is adequate to achieve optimal efficacy with fixed-dose artemether-lumefantrine: a review of the evidence. Malar. J. 7, 244 (2008).
16. Clark RL, Lerman SA, Cox EM, Gristwood WE, White TE. Developmental toxicity of artesunate in the rat: comparison to other artemisinins, comparison of embryotoxicity and kinetics by oral and intravenous routes, and relationship to maternal reticulocyte count. Birth Defects Res. B. Dev. Reprod. Toxicol. 83(4), 397-406 (2008).
17. White TE, Bushdid PB, Ritter S, Laffan SB, Clark RL. Artesunate-induced depletion of embryonic erythroblasts precedes embryolethality and teratogenicity in vivo. Birth Defects Res. B Dev. Reprod. Toxicol. 77(5), 413-429 (2006).
18. Smithuis F, Kyaw MK, Phe O et al. Efficacy and effectiveness of dihydroartemisinin- piperaquine versus artesunatemefloquine in falciparum malaria: an open-label randomised comparison. Lancet 367(9528), 2075-2085 (2006).
19. Mizuno Y, Kato Y, Kudo K, Kano S. First case of treatment failure of artemether-lumefantrine in a Japanese traveler with imported falciparum malaria. Jpn J. Infect. Dis. 62(2), 139-141 (2009).
20. Abdulla S, Sagara I, Borrmann S et al. Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial. Lancet 372(9652), 1819-1827 (2008).
21. White NJ, van Vugt M, Ezzet F. Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether- lumefantrine. Clin. Pharmacokinet. 37(2), 105-125 (1999).
22. Djimde A, Lefevre G. Understanding the pharmacokinetics of Coartem. Malar. J. 8(Suppl. 1), S4 (2009).
23. McGready R, Stepniewska K, Lindegardh N et al. The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria. Eur. J. Clin. Pharmacol. 62(12), 1021-1031 (2006).
24. Piola P, Nabasumba C, Turyakira E et al. Efficacy and safety of artemether-lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomized, non-inferiority trial. Lancet Infect. Dis. 10(11), 762-769 (2010).
25. Tarning J, McGready R, Lindegardh N et al. Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. Antimicrob. Agents Chemother. 53(9), 3837-3846 (2009).
26. McGready R, Tan SO, Ashley EA et al. A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated Plasmodium falciparum treatment in pregnancy. PLoS Med. 5(12), e253 (2008).
27. Mutabingwa TK, Muze K, Ord R et al. Randomized trial of artesunate+amodiaquine, sulfadoxinepyrimethamine+ amodiaquine, chlorproguanal- dapsone and SP for malaria in pregnancy in Tanzania. PLoS ONE 4(4), e5138 (2009).
28. Ades V. Safety, pharmacokinetics and efficacy of artemisinins in preganancy. Infect. Dis. Reports 3, 37-43 (2011).
29. Nosten F, McGready R, Mutabingwa T. Case management of malaria in pregnancy. Lancet Infect. Dis. 7(2), 118-125 (2007).
30. Kaye DK, Nshemerirwe R, Mutyaba TS, Ndeezi G. A randomized clinical trial comparing safety, clinical and parasitological response to artemether- lumefantrine and chlorproguanil-dapsone in treatment of uncomplicated malaria in pregnancy in Mulago hospital, Uganda. J. Infect. Dev. Ctries 2(2), 135-139 (2008).
31. Tarning J, Kloprogge F, Piola P et al. Population pharmacokinetics of artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda. Malar. J. 11, 293 (2012).
32. Gonzalez R, Ataide R, Naniche D, Menendez C, Mayor A. HIV and malaria interactions: where do we stand? Expert Rev. Anti Infect. Ther. 10(2), 153-165 (2012).
33. Kredo T, Mauff K, Van der Walt JS et al. Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients. Antimicrob. Agents Chemother. 55(12), 5616-5623 (2011).
34. Falade C, Manyando C. Safety profile of Coartem: the evidence base. Malar. J. 8(Suppl. 1), S6 (2009).
35. Panossian LA, Garga NI, Pelletier D. Toxic brainstem encephalopathy after artemisinin treatment for breast cancer. Ann. Neurol. 58(5), 812-813 (2005).
36. Miller LG, Panosian CB. Ataxia and slurred speech after artesunate treatment for falciparum malaria. N. Engl. J. Med. 336(18), 1328 (1997).
37. Franco-Paredes C, Dismukes R, Nicolls D, Kozarsky PE. Neurotoxicity due to antimalarial therapy associated with misdiagnosis of malaria. Clin. Infect. Dis. 40(11), 1710-1711 (2005).
38. Bakshi R, Hermeling-Fritz I, Gathmann I, Alter E. An integrated assessment of the clinical safety of artemether-lumefantrine: a new oral fixed-dose combination antimalaria drug. Trans. Roy. Soc. Trop. Med. Hyg. 94, 419-424 (2000).
39. Manyando C, Mkandawire R, Puma L et al. Safety of artemether-lumefantrine in pregnant women with malaria: results of a prospective cohort study in Zambia. Malar. J. 9, 249 (2010).
40. Gurkov R, Eshetu T, Miranda IB et al. Ototoxicity of artemether- lumefantrine in the treatment of falciparum malaria: a randomized trial. Malaria J. 7, 179 (2008).
41. Chen LJ, Wang MY, Sun WK, Liu MZ. Embryotoxicity and teratogenicity studies on artemether in mice, rats and rabbits. Zhongguo Yao Li Xue Bao 5(2), 118-122 (1984).
42. Clark RL, Arima A, Makori N et al. Artesunate: developmental toxicity and toxicokinetics in monkeys. Birth Defects Res. B Dev. Reprod. Toxicol. 83(4), 418-434 (2008).
43. Manyando C, Kayentao K, D'Alessandro U, Okafor HU, Juma E, Hamed K. A systematic review of the safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy. Malar. J. 11, 141 (2012).
44. Dellicour S, Hall S, Chandramohan D, Greenwood B. The safety of artemisinins during pregnancy: a pressing question. Malar. J. 6, 15 (2007).
45. Rulisa S, Kaligirwa N, Agaba S, Karema C, Mens PF, de Vries PJ. Pharmacovigilance of artemether-lumefantrine in pregnant women followed until delivery in Rwanda. Malar. J. 11, 225 (2012).
46. McGready R, Cho T, Keo NK et al. Artemisinin antimalarials in pregnancy: a prospective treatment study of 539 episodes of multidrug-resistant Plasmodium falciparum. Clin. Infect. Dis. 33(12), 2009-2016 (2001).
47. McGready R, Lee SJ, Wiladphaingern J et al. Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a populationbased study. Lancet Infect. Dis. 12(5), 388-396 (2012).
48. Yavo W, Faye B, Kuete T et al. Multicentric assessment of the efficacy and tolerability of dihydroartemisinin-piperaquine compared to artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa. Malar. J. 10, 198 (2011).
49. Sowunmi A, Oduol AM, Ogundahunsi OA et al. Randomized trial of artemether versus artemether and mefloquine for the treatment of chloroquine/ sulfadoxinepyrimethamine- resistant falciparum malaria during pregnancy. J. Obstet. Gynaecol. 18, 322-327 (1998).
50. Adam I, Elwasila E, Mohammed Ali DA, Elansari E, Elbashir MI. Artemether in the treatment of falciparum malaria during pregnancy in eastern Sudan. Trans. R. Soc. Trop. Med. Hyg. 98(9), 509-513 (2004).
51. Wang TY. Follow-up observation on the therapeutic effects and remote reactions of artemisinin (Qinghaosu) and artemether in treating malaria in pregnant woman. J. Tradit. Chin. Med. 9(1), 28-30 (1989).
52. Adam I, Elhassan EM, Omer EM, Abdulla MA, Mahgoub HM, Adam GK. Safety of artemisinins during early pregnancy, assessed in 62 Sudanese women. Ann. Trop. Med. Parasitol. 103(3), 205-210 (2009).
53. Sangare LR, Weiss NS, Brentlinger PE et al. Patterns of anti-malarial drug treatment among pregnant women in Uganda. Malar. J. 10, 152 (2011).
54. WHO. Country antimalarial drug policies by region. Map created by Worldwide Antimalarial Resistance Network (WWARN) based on data available on WHO website and last updated February 2011. www.who.int/malaria/am-drug-policies- by-region-afro